Vertex Pharmaceuticals (VRTX) smashed first-quarter expectations late Thursday, reiterated its 2018 guidance and announced that another triple-pill regimen for cystic fibrosis will head into Phase 3 studies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,